Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Retained Earnings of -$336.7 million for Q4 2025, down 93.09% year-over-year from -$4.9 billion in Q4 2024, and down 23.66% quarter-over-quarter from -$272.3 million in Q3 2025.
Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$336.7 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 93.09% year-over-year to -$336.7 million; the TTM figure through Dec 2025 stood at -$336.7 million (down 93.09% YoY), while the FY2025 annual figure was -$336.7 million, down 93.09% from the prior year.
- Retained Earnings for Q4 2025 stood at -$336.7 million, down from -$272.3 million in the prior quarter.
- The five-year high for Retained Earnings was -$45.9 million in Q4 2022, with the low at -$434.5 million in Q2 2023.
- The 5-year median for Retained Earnings is -$253.7 million (2021), against an average of -$232.9 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 85.91% in 2022, then tumbled 97.58% in 2025.
- Dianthus Therapeutics' Retained Earnings stood at -$325.6 million in 2021, then jumped by 85.91% to -$45.9 million in 2022, then slumped by 94.96% to -$89.4 million in 2023, then slumped by 95.02% to -$174.4 million in 2024, then slumped by 93.09% to -$336.7 million in 2025.
- Business Quant data shows DNTH's Retained Earnings at -$336.7 million in Q4 2025, -$272.3 million in Q3 2025, and -$235.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | -336.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -336.73 Mn |
| Sep 30, 2025 | -272.30 Mn |
| Jun 30, 2025 | -235.53 Mn |
| Mar 31, 2025 | -203.90 Mn |
| Dec 31, 2024 | -174.39 Mn |
| Sep 30, 2024 | -146.00 Mn |
| Jun 30, 2024 | -120.80 Mn |
| Mar 31, 2024 | -103.20 Mn |
| Dec 31, 2023 | -89.42 Mn |
| Sep 30, 2023 | -78.90 Mn |
| Jun 30, 2023 | -434.50 Mn |
| Mar 31, 2023 | -431.20 Mn |
| Dec 31, 2022 | -45.87 Mn |
| Sep 30, 2022 | -78.90 Mn |
| Jun 30, 2022 | -365.80 Mn |
| Mar 31, 2022 | -348.52 Mn |
| Dec 31, 2021 | -325.57 Mn |
| Sep 30, 2021 | -306.30 Mn |
| Jun 30, 2021 | -288.85 Mn |
| Mar 31, 2021 | -271.92 Mn |